In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Heart failure class at presentation: a predictor of prognosis in patients with infective endocarditis

Session Poster Session 4

Speaker Ines Silveira

Event : Heart Failure 2016

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease
  • Session type : Poster Session

Authors : I Silveira (Porto,PT), R Santos B (Porto,PT), B Brochado (Porto,PT), M Trepa (Porto,PT), A Luz (Porto,PT), S Torres (Porto,PT)

I Silveira1 , R Santos B1 , B Brochado1 , M Trepa1 , A Luz1 , S Torres1 , 1Hospital Center of Porto, Cardiology - Porto - Portugal ,

European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 478

Purpose: Despite diagnostic and therapeutic advances infective endocarditis remains an important cause of morbidity and mortality worldwide. To recognise predictors of poor prognosis at presentation is crucial in the management of these patients. Methods: Retrospective, single center study, of patients admitted for infective endocarditis (EI) in a tertiary hospital, during a ten years period. The patients were divided in two groups according to heart failure classification by New York Heart Association (NYHA) criterions at admission: Group 1 (NYHA class I/II) and Group 2 (NYHA class III/IV). For each group we analyse clinical, echocardiographic parameters and in-hospital and one year outcomes. Results: 103 patients with EI were included, 62,1% men, mean age 65,8 ± 17,2 years. Native valve EI was present in 85% of cases with same prevalence of aortic and mitral valve involvement (40%). Perivalvular complication were reported in 17,6% (14,7% abscess and 2,9% fistulas). According to division in heart failure NYHA class at presentation Group 1 included 72 patients and Group 2 31 patients. There were no significant differences between groups regarding gender, type and location of EI or perivalvular complication, but with a higher proportion of severe valvular regurgitation in Group 2 (18,3 vs 28,7% p = 0.027). Patients in Group 2 were older (62,6 ± 17,1 vs 73,2 ± 15,1 years p = 0.003), had a lower creatinine clearance at admission (68,1  ± 29,4 vs 44,6 ± 23,9 p < 0.001) and developed more frequent acute kidney injury ( 25,4 vs 51,6% p = 0.010), with no significant differences in diabetes, immunosuppression or use of IV drugs. Group 2 had also a higher percentage of patients with atrial fibrillation (28,2% vs 44,8% p=0,010) and with moderate to severe left ventricular dysfunction (4,3% vs 20% p=0,020). We found same proportion of embolic events, but with higher rates of sepsis and cardiogenic shock in Group 2. In-hospital and one year mortality rate were higher in Group 2 (21,4% vs 45,2% p = 0.015 and 6,0% vs 28,6% p = 0.036, respectively). After multivariate analysis acute kidney injury and NYHA class remained as independent predictors of mortality (OR: 3,44; 95% CI: 1,22 to 9,66; p = 0.019 and OR:2,37; 95% CI:0,72 to 7,83; p = 0.043). Conclusion: NYHA class at admission proved to be a strong predictor of prognosis in patients with EI. Presentation in class III/IV NYHA reflects a type of patients with higher comorbidities and in-hospital complications, with a consequent higher mortality rates.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are